2024
The literacy barrier in clinical trial consents: a retrospective analysis
Mirza F, Wu E, Abdulrazeq H, Connolly I, Tang O, Zogg C, Williamson T, Galamaga P, Roye G, Sampath P, Telfeian A, Qureshi A, Groff M, Shin J, Asaad W, Libby T, Gokaslan Z, Kohane I, Zou J, Ali R. The literacy barrier in clinical trial consents: a retrospective analysis. EClinicalMedicine 2024, 75: 102814. DOI: 10.1016/j.eclinm.2024.102814.Peer-Reviewed Original ResearchClinical trialsClinical trial consent formsDropout ratesReading levelRisk-adjusted analysisInterventional clinical trialsConsent formTrial dropout ratesGrade level increasesReading comprehension skillsRetrospective analysisClinical trial participationHigh dropout ratesFunded trialsExploratory analysis
2018
Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies
Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunology, Immunotherapy 2018, 67: 1833-1844. PMID: 30191256, PMCID: PMC6249064, DOI: 10.1007/s00262-018-2241-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalComorbidityDisease ManagementFemaleHealth Care SurveysHumansImmunotherapyMaleMelanomaMiddle AgedMolecular Targeted TherapyNeoplasm StagingOdds RatioProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRegistriesSymptom AssessmentUnited StatesYoung AdultConceptsStage 4 melanomaOverall survivalInitial approvalCutaneous melanomaLandmark survival analysisSubstantial clinical efficacyImproved overall survivalMetastatic cutaneous melanomaNational Cancer DatabaseStage 4 diseaseCheckpoint blockade immunotherapySurvival of patientsRisk-adjusted analysisBlockade immunotherapyCheckpoint blockadeNovel immunotherapiesMultivariable analysisClinical efficacyMetastatic melanomaNational cohortCancer DatabaseUninsured patientsClinical trialsPatientsSurvival analysisImproved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort
Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, Aizer AA, Smith TR. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunology Research 2018, 6: 1039-1045. PMID: 30002157, PMCID: PMC6230261, DOI: 10.1158/2326-6066.cir-18-0067.Peer-Reviewed Original ResearchConceptsMelanoma brain metastasesCheckpoint blockade immunotherapyMBM patientsOverall survivalBlockade immunotherapyStage 4 melanomaNational Cancer DatabaseManagement of patientsKaplan-Meier techniqueLarge national cohortEarly clinical trialsBrain metastasesExtracranial metastasesSurvival benefitAdvanced melanomaOS improvementNational cohortCancer DatabaseClinical trialsNovel therapiesU.S. cancerPatientsTherapy trialsProportional hazardsFDA approval